20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ascendis Pharma AS (ASND) operates in the BIOTECHNOLOGY industry and is headquartered in Hellerup, Denmark with about 1,189 employees. Its market capitalization is roughly $16 billion. In the fiscal year ended 2025-12-31, ASND reported €692M in revenue and (€219M) in net income.
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally.
Interactive charts & full statements → Open the ASND valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €1.0B | €692M | €364M | €267M | €51M | €8M | €7M | €13M | €11M | €2M | €5M | €8M | €14M | €20M | €16M |
| Gross Profit | €950M | €589M | €319M | €222M | €39M | €4M | €7M | €13M | €11M | €2M | €5M | €8M | €14M | €20M | €16M |
| Gross Margin % | 90.6% | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | €266M | (€131M) | (€279M) | (€456M) | (€562M) | (€452M) | (€331M) | (€227M) | (€155M) | (€112M) | (€73M) | (€42M) | (€12M) | €5M | €2M |
| Operating Margin % | 25.4% | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% | -515.2% | -85.7% | 25.9% | 9.7% |
| Net Income | €753M | (€219M) | (€378M) | (€481M) | (€583M) | (€384M) | (€419M) | (€218M) | (€130M) | (€124M) | (€69M) | (€33M) | (€10M) | €4M | €1M |
| Net Margin % | 71.8% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% | -405.5% | -69.1% | 20.0% | 8.0% |
| EBITDA | — | (€110M) | (€290M) | (€411M) | (€529M) | (€365M) | (€408M) | (€210M) | (€150M) | (€110M) | (€72M) | (€33M) | (€11M) | €6M | €2M |
| Earnings Per Share (EPS) | €11.20 | €-3.61 | €-6.53 | €-8.55 | €-10.40 | €-7.00 | €-8.28 | €-4.69 | €-3.17 | €-3.68 | €-2.58 | €-1.39 | €-0.57 | €0.38 | €0.12 |
| Shares Outstanding (M) | — | 61M | 58M | 56M | 56M | 55M | 51M | 47M | 41M | 34M | 27M | 24M | 17M | 11M | 11M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €339M | €251M | €245M | €214M | €158M | €101M | €174M | €58M | €36M |
| Gross Profit | €312M | €229M | €218M | €191M | €127M | €83M | €160M | €47M | €25M |
| Gross Margin % | 92.0% | 91.4% | 88.9% | 89.5% | 80.1% | 82.7% | 91.9% | 80.6% | 68.2% |
| Operating Income (EBIT) | €220M | €25M | €10M | €11M | (€53M) | (€104M) | €0M | (€97M) | (€133M) |
| Operating Margin % | 64.9% | 10.1% | 4.0% | 5.1% | -33.5% | -103.2% | 0.2% | -167.3% | -370.2% |
| Net Income | €207M | €640M | (€33M) | (€61M) | (€39M) | (€95M) | (€38M) | (€99M) | (€109M) |
| Net Margin % | 61.1% | 255.2% | -13.6% | -28.5% | -24.6% | -93.7% | -22.1% | -171.5% | -303.9% |
| EBITDA | — | €24M | €40M | (€53M) | €2M | (€44M) | (€38M) | (€71M) | (€88M) |
| Earnings Per Share (EPS) | €2.83 | €9.91 | €-0.54 | €-1.00 | €-0.61 | €-1.58 | €-0.64 | €-1.69 | €-1.91 |
| Shares Outstanding (M) | — | 65M | 61M | 61M | 64M | 60M | 60M | 59M | 57M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | €347M | €52M | (€306M) | (€467M) | (€496M) | (€418M) | (€272M) | (€176M) | (€139M) | (€95M) | (€60M) | (€43M) | (€18M) | €6M | (€1M) |
| Capital Expenditures (CapEx) | — | €8M | €1M | €2M | €14M | €24M | €22M | €5M | €3M | €1M | €1M | €1M | €0M | €1M | €0M |
| Free Cash Flow (FCF) | — | €44M | (€308M) | (€470M) | (€510M) | (€442M) | (€293M) | (€181M) | (€141M) | (€96M) | (€61M) | (€45M) | (€19M) | €5M | (€1M) |
| FCF Margin % | — | 6.3% | -84.6% | -176.1% | -997.0% | -5681.2% | -4215.4% | -1354.0% | -1336.8% | -6277.1% | -1321.1% | -548.2% | -134.5% | 25.1% | -6.0% |
| Dividends Paid | — | — | — | — | €5M | €33M | — | €0M | €0M | €0M | €0M | €0M | €0M | — | — |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | €282M | (€8M) | €71M | €2M | (€7M) | (€14M) | (€87M) | (€56M) | (€61M) |
| Capital Expenditures (CapEx) | — | €8M | €3M | €0M | €4M | €1M | €0M | €0M | €0M |
| Free Cash Flow (FCF) | — | (€16M) | €67M | €2M | (€12M) | (€15M) | (€88M) | (€57M) | (€62M) |
| FCF Margin % | — | -6.3% | 27.5% | 1.0% | -7.4% | -14.9% | -50.3% | -97.9% | -171.3% |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | €2.3B | €1.3B | €1.2B | €826M | €1.1B | €1.1B | €980M | €677M | €319M | €211M | €190M | €132M | €59M | €27M | €25M | €23M |
| Cash & Cash Equivalents | €812M | €616M | €560M | €392M | €445M | €446M | €585M | €598M | €278M | €195M | €180M | €120M | €50M | €19M | €15M | €16M |
| Total Liabilities | €850M | €1.5B | €1.3B | €971M | €826M | €201M | €141M | €80M | €39M | €24M | €13M | €11M | €13M | €20M | €24M | €23M |
| Total Debt (Short + Long-Term) | €450M | €872M | €857M | €970M | €910M | €112M | €7M | €6M | €0M | €0M | €0M | €0M | €0M | €0M | €0M | €0M |
| Total Shareholders' Equity | €1.4B | (€163M) | (€106M) | (€146M) | €263M | €884M | €839M | €597M | €280M | €187M | €177M | €120M | €46M | €6M | €2M | €0M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ASND viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms